Actively Recruiting
Repeated Examinations for Typing Pulmonary Embolism (RE-TyPE)
Led by Sahlgrenska University Hospital · Updated on 2026-04-06
400
Participants Needed
3
Research Sites
104 weeks
Total Duration
On this page
Sponsors
S
Sahlgrenska University Hospital
Lead Sponsor
G
Gothia Forum - Center for Clinical Trial
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying pulmonary embolism (PE), a serious heart and lung condition, focusing on patients with intermediate-high risk PE. The study aims to better understand the early course of this condition and how changes in tests like biomarkers, ECG, and echocardiography during the first 48 hours relate to patient outcomes. It also seeks to create a long-term follow-up system for all PE patients treated at Sahlgrenska University Hospital to improve care quality and outcomes. The study has two parts: Cohort A includes hospitalized patients with intermediate-high risk PE who undergo repeated tests and monitoring during the first three days after diagnosis, including vital signs, echocardiography, ECG, blood tests, and oxygen or circulatory support if needed. Cohort B includes all PE patients diagnosed at the hospital, who are followed over time with baseline and follow-up assessments at about 90 days and beyond 12 months. Cohort B patients not in Cohort A mainly have baseline and longer-term data collected. Participants will have repeated examinations during hospital stays and outpatient visits, including echocardiography and ECG. Researchers will collect clinical data, laboratory samples, and measure outcomes such as clinical deterioration and bleeding within 7 days, plus longer-term outcomes like recurrence of PE, quality of life, and chronic complications. The study will follow patients up to a year or more to assess these outcomes and improve future PE care.
CONDITIONS
Brief Title
Repeated Examinations for Typing Pulmonary Embolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (18 years or older) diagnosed with or followed for pulmonary embolism at Sahlgrenska University Hospital
- Able to provide written informed consent
You will not qualify if you...
- Patients with low risk, intermediate-low risk, or high risk pulmonary embolism (not intermediate-high risk)
- More than 48 hours have passed since hospital arrival for pulmonary embolism
- Expected inability to comply with the study protocol (for example, due to dementia)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - Up to 48 hours from pulmonary embolism event
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Day 0 to Day 2
Participants with intermediate-high risk pulmonary embolism undergo serial clinical examinations including vital signs, ECG, echocardiography, biomarkers, and other assessments during their hospital stay to characterize the early clinical course of pulmonary embolism.
3 visits (in-person) on Day 0, Day 1, and Day 2
Duration - Up to more than 12 months
Participants are followed up to assess clinical outcomes and patient-reported measures at intermediate and long-term timepoints after initial diagnosis or hospitalization.
Visits at approximately Day 30, Day 90, and beyond 12 months (in-person or outpatient)
Trial Site Locations
Total: 3 locations
1
Sahlgrenska University Hospital/Mölndal
Gothenburg, Region Västra Götaland, Sweden
Not Yet Recruiting
2
Sahlgrenska University Hospital/Sahlgrenska
Gothenburg, Region Västra Götaland, Sweden
Actively Recruiting
3
Sahlgrenska University Hospital/Östra
Gothenburg, Region Västra Götaland, Sweden
Not Yet Recruiting
Research Team
R
Rickard Zeijlon, MD, PhD
M
Mazdak Tavoly, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here